{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:20:37Z","timestamp":1772853637321,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010803","name":"Department of Biotechnology, Government of West Bengal","doi-asserted-by":"publisher","award":["GAP-392"],"award-info":[{"award-number":["GAP-392"]}],"id":[{"id":"10.13039\/501100010803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Herpes simplex virus (HSV) usually produces cytopathic effect (CPE) within 24-72\u00a0h post-infection (P.I.). Clinical isolates from recurrent HSV infections in patients on Acyclovir therapy were collected between 2016 and 2019 and tested in cell cultures for cytopathic effects and further in-depth characterization. Fourteen such isolates did not show any CPE in A549 or Vero cell lines even at 120\u00a0h P.I. However, these cultures remained positive for HSV-DNA after several passages. Sequence analysis revealed that the non-CPE isolates were all HSV-1. Analysis of the thymidine kinase gene from the isolates revealed several previously reported and two novel ACV-resistant mutations. Immunofluorescence and Western blot data revealed a low-level expression of the immediate early protein, ICP4. Late proteins like ICP5 or capsid protein, VP16 were almost undetectable in these isolates. AFM imaging revealed that the non-CPE viruses had structural deformities compared to wild-type HSV-1. Our findings suggest that these strains are manifesting an unusual phenomenon of being non-CPE herpesviruses with low level of virus protein expressions over several passages. Probably these HSV-1 isolates are evolving towards a more \u201ccryptic\u201d form to establish chronic infection in the host thereby unraveling yet another strategy of herpesviruses to evade the host immune system.<\/jats:p>","DOI":"10.1038\/s41598-022-05188-w","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T11:03:10Z","timestamp":1643108590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Non-cytopathic herpes simplex virus type-1 isolated from acyclovir-treated patients with recurrent infections"],"prefix":"10.1038","volume":"12","author":[{"given":"Subrata","family":"Roy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soumi","family":"Sukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"De","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhajit","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"5188_CR1","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1086\/340041","volume":"185","author":"F Xu","year":"2002","unstructured":"Xu, F. et al. Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988\u20131994. J. Infect. Dis. 185, 1019\u20131024 (2002).","journal-title":"J. Infect. Dis."},{"key":"5188_CR2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2471\/BLT.19.237149","volume":"98","author":"C James","year":"2020","unstructured":"James, C. et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull. World Health Organ. 98, 315\u2013329 (2020).","journal-title":"Bull. World Health Organ."},{"key":"5188_CR3","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jama.296.8.964","volume":"296","author":"F Xu","year":"2006","unstructured":"Xu, F. et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296, 964 (2006).","journal-title":"JAMA"},{"key":"5188_CR4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1128\/CMR.10.3.419","volume":"10","author":"EK Wagner","year":"1997","unstructured":"Wagner, E. K. & Bloom, D. C. Experimental investigation of herpes simplex virus latency. Clin. Microbiol. Rev. 10, 419\u2013443 (1997).","journal-title":"Clin. Microbiol. Rev."},{"key":"5188_CR5","doi-asserted-by":"crossref","first-page":"e2230","DOI":"10.1371\/journal.pone.0002230","volume":"3","author":"LJ Abu-Raddad","year":"2008","unstructured":"Abu-Raddad, L. J. et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One 3, e2230 (2008).","journal-title":"PLoS One"},{"key":"5188_CR6","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1056\/NEJM198304213081602","volume":"308","author":"YJ Bryson","year":"1983","unstructured":"Bryson, Y. J. et al. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. N. Engl. J. Med. 308, 916\u2013921 (1983).","journal-title":"N. Engl. J. Med."},{"key":"5188_CR7","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJM198406143102402","volume":"310","author":"JM Douglas","year":"1984","unstructured":"Douglas, J. M. et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N. Engl. J. Med. 310, 1551\u20131556 (1984).","journal-title":"N. Engl. J. Med."},{"key":"5188_CR8","doi-asserted-by":"publisher","DOI":"10.1017\/cbo9780511545313.065","author":"DW Kimberlin","year":"2020","unstructured":"Kimberlin, D. W. & Whitley, R. J. Antiviral therapy of HSV-1 and -2. Human Herpesviruses https:\/\/doi.org\/10.1017\/cbo9780511545313.065 (2020).","journal-title":"Human Herpesviruses"},{"key":"5188_CR9","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1590\/abd1806-4841.20142574","volume":"89","author":"C Nozawa","year":"2014","unstructured":"Nozawa, C. et al. Herpes simplex virus: isolation, cytopathological characterization and antiviral sensitivity. An. Bras. Dermatol. 89, 448\u2013452 (2014).","journal-title":"An. Bras. Dermatol."},{"key":"5188_CR10","doi-asserted-by":"crossref","first-page":"7653","DOI":"10.1128\/JVI.78.14.7653-7666.2004","volume":"78","author":"X Jing","year":"2004","unstructured":"Jing, X., Cerveny, M., Yang, K. & He, B. Replication of herpes simplex virus 1 depends on the gamma 134.5 functions that facilitate virus response to interferon and egress in the different stages of productive infection. J. Virol. 78, 7653\u20137666 (2004).","journal-title":"J. Virol."},{"key":"5188_CR11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.antiviral.2008.04.005","volume":"80","author":"S Biswas","year":"2008","unstructured":"Biswas, S., Tiley, L. S., Zimmermann, H., Birkmann, A. & Field, H. J. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity. Antiviral Res. 80, 81\u201385 (2008).","journal-title":"Antiviral Res."},{"key":"5188_CR12","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1099\/vir.0.011221-0","volume":"90","author":"S Biswas","year":"2009","unstructured":"Biswas, S., Miguel, R. N., Sukla, S. & Field, H. J. A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure. J. Gen. Virol. 90, 1937\u20131942 (2009).","journal-title":"J. Gen. Virol."},{"key":"5188_CR13","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/jac\/dkn057","volume":"61","author":"S Biswas","year":"2008","unstructured":"Biswas, S. et al. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target. J. Antimicrob. Chemother. 61, 1044\u20131047 (2008).","journal-title":"J. Antimicrob. Chemother."},{"key":"5188_CR14","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00705-007-0964-7","volume":"152","author":"S Biswas","year":"2007","unstructured":"Biswas, S., Jennens, L. & Field, H. J. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57\u20131293 are associated with increased or decreased virus growth characteristics in tissue culture. Arch. Virol. 152, 1489\u20131500 (2007).","journal-title":"Arch. Virol."},{"key":"5188_CR15","doi-asserted-by":"crossref","first-page":"12273","DOI":"10.1128\/JVI.01959-15","volume":"89","author":"S Burrel","year":"2015","unstructured":"Burrel, S. et al. Genetic diversity within Alphaherpesviruses: Characterization of a novel variant of herpes simplex virus 2. J. Virol. 89, 12273\u201312283 (2015).","journal-title":"J. Virol."},{"key":"5188_CR16","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/606028","volume":"200","author":"R Duan","year":"2009","unstructured":"Duan, R. et al. Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis. J. Infect. Dis. 200, 1402\u20131414 (2009).","journal-title":"J. Infect. Dis."},{"key":"5188_CR17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jcv.2013.03.014","volume":"57","author":"M van Velzen","year":"2013","unstructured":"van Velzen, M. et al. Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients. J. Clin. Virol. 57, 215\u2013221 (2013).","journal-title":"J. Clin. Virol."},{"key":"5188_CR18","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1128\/AAC.00669-10","volume":"54","author":"S Burrel","year":"2010","unstructured":"Burrel, S., Deback, C., Agut, H. & Boutolleau, D. Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. Antimicrob. Agents Chemother. 54, 4833\u20134842 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"5188_CR19","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1128\/JCM.01714-13","volume":"51","author":"S Burrel","year":"2013","unstructured":"Burrel, S. et al. Molecular characterization of herpes simplex virus 2 strains by analysis of microsatellite polymorphism. J. Clin. Microbiol. 51, 3616\u20133623 (2013).","journal-title":"J. Clin. Microbiol."},{"key":"5188_CR20","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/infdis\/jit350","volume":"208","author":"M van Velzen","year":"2013","unstructured":"van Velzen, M. et al. Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis. J. Infect. Dis. 208, 1359\u20131365 (2013).","journal-title":"J. Infect. Dis."},{"key":"5188_CR21","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.antiviral.2019.05.012","volume":"168","author":"T Labrunie","year":"2019","unstructured":"Labrunie, T. et al. UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients. Antiviral Res. 168, 114\u2013120 (2019).","journal-title":"Antiviral Res."},{"key":"5188_CR22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.antiviral.2013.09.012","volume":"100","author":"S Burrel","year":"2013","unstructured":"Burrel, S. et al. Surveillance of herpes simplex virus resistance to antivirals: a 4-year survey. Antiviral Res. 100, 365\u2013372 (2013).","journal-title":"Antiviral Res."},{"key":"5188_CR23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2003.08.018","volume":"61","author":"D Chibo","year":"2004","unstructured":"Chibo, D., Druce, J., Sasadeusz, J. & Birch, C. Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus. Antiviral Res. 61, 83\u201391 (2004).","journal-title":"Antiviral Res."},{"key":"5188_CR24","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.00615-10","volume":"55","author":"J Piret","year":"2011","unstructured":"Piret, J. & Boivin, G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob. Agents Chemother. 55, 459\u2013472 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"5188_CR25","first-page":"307","volume":"37","author":"R Kaur","year":"2005","unstructured":"Kaur, R., Gupta, N. & Baveja, U. K. Seroprevalence of HSV1 and HSV2 infections in family planning clinic attenders. J. Commun. Dis. 37, 307\u2013309 (2005).","journal-title":"J. Commun. Dis."},{"key":"5188_CR26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1155\/2005\/318294","volume":"16","author":"A Singh","year":"2005","unstructured":"Singh, A., Preiksaitis, J., Ferenczy, A. & Romanowski, B. The laboratory diagnosis of herpes simplex virus infections. Can. J. Infect. Dis. Med. Microbiol. 16, 92 (2005).","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"5188_CR27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1128\/jcm.24.2.265-268.1986","volume":"24","author":"CD Smith","year":"1986","unstructured":"Smith, C. D., Craft, D. W., Shiromoto, R. S. & Yan, P. O. Alternative cell line for virus isolation. J. Clin. Microbiol. 24, 265\u2013268 (1986).","journal-title":"J. Clin. Microbiol."},{"key":"5188_CR28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0166-0934(89)90166-3","volume":"23","author":"GL Woods","year":"1989","unstructured":"Woods, G. L. & Yam, P. Detection of herpes simplex virus in clinical specimens using a DNA probe after centrifugal inoculation of A549 cells. J. Virol. Methods 23, 339\u2013343 (1989).","journal-title":"J. Virol. Methods"},{"key":"5188_CR29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.antiviral.2014.03.015","volume":"107","author":"A Schubert","year":"2014","unstructured":"Schubert, A. et al. Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes. Antiviral Res. 107, 16\u201322 (2014).","journal-title":"Antiviral Res."},{"key":"5188_CR30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1099\/0022-1317-25-2-313","volume":"25","author":"D Enlander","year":"1974","unstructured":"Enlander, D., Drew, L., Hoo, R., Everhart, T. E. & Scott, T. The cytopathic effect of herpes simplex virus on HEp-2 cells as shown by scanning electron microscopy. J. Gen. Virol. 25, 313\u2013316 (1974).","journal-title":"J. Gen. Virol."},{"key":"5188_CR31","doi-asserted-by":"crossref","first-page":"e114989","DOI":"10.1371\/journal.pone.0114989","volume":"10","author":"KJ Looker","year":"2015","unstructured":"Looker, K. J. et al. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS One 10, e114989 (2015).","journal-title":"PLoS One"},{"key":"5188_CR32","first-page":"91","volume":"6","author":"C Mendoza-Rodriguez","year":"2020","unstructured":"Mendoza-Rodriguez, C. et al. Identification and pathogenic potential of orofacial herpetic clinical isolates in northeast mexico. Int. J. Clin. Exp. Med. Sci. 6, 91\u201395 (2020).","journal-title":"Int. J. Clin. Exp. Med. Sci."},{"key":"5188_CR33","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/0042-6822(88)90308-X","volume":"163","author":"Q Liu","year":"1988","unstructured":"Liu, Q. & Summers, W. C. Site-directed mutagenesis of a nucleotide-binding domain in HSV-1 thymidine kinase: effects on catalytic activity. Virology 163, 638\u2013642 (1988).","journal-title":"Virology"},{"key":"5188_CR34","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1128\/JVI.76.4.1537-1547.2002","volume":"76","author":"TC Mettenleiter","year":"2002","unstructured":"Mettenleiter, T. C. Herpesvirus Assembly and Egress. J. Virol. 76, 1537\u20131547 (2002).","journal-title":"J. Virol."},{"key":"5188_CR35","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1128\/JVI.74.14.6287-6299.2000","volume":"74","author":"KL Mossman","year":"2000","unstructured":"Mossman, K. L., Sherburne, R., Lavery, C., Duncan, J. & Smiley, J. R. Evidence that herpes simplex virus VP16 is required for viral egress downstream of the initial envelopment event. J. Virol. 74, 6287\u20136299 (2000).","journal-title":"J. Virol."},{"key":"5188_CR36","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1128\/JVI.00011-11","volume":"85","author":"DC Johnson","year":"2011","unstructured":"Johnson, D. C., Wisner, T. W. & Wright, C. C. Herpes simplex virus glycoproteins gB and gD function in a redundant fashion to promote secondary envelopment. J. Virol. 85, 4910\u20134926 (2011).","journal-title":"J. Virol."},{"key":"5188_CR37","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1128\/JVI.74.15.7137-7145.2000","volume":"74","author":"R Nixdorf","year":"2000","unstructured":"Nixdorf, R., Klupp, B. G., Karger, A. & Mettenleiter, T. C. Effects of truncation of the carboxy terminus of pseudorabies virus glycoprotein B on infectivity. J. Virol. 74, 7137\u20137145 (2000).","journal-title":"J. Virol."},{"key":"5188_CR38","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1128\/jvi.65.3.1090-1098.1991","volume":"65","author":"BC Herold","year":"1991","unstructured":"Herold, B. C., WuDunn, D., Soltys, N. & Spear, P. G. Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity. J. Virol. 65, 1090\u20131098 (1991).","journal-title":"J. Virol."},{"key":"5188_CR39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.virol.2018.07.011","volume":"522","author":"S Jb","year":"2018","unstructured":"Jb, S. & Ar, C. Strength in diversity: understanding the pathways to herpes simplex virus reactivation. Virology 522, 81\u201391 (2018).","journal-title":"Virology"},{"key":"5188_CR40","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1073\/pnas.1910537117","volume":"117","author":"EM Cohen","year":"2020","unstructured":"Cohen, E. M., Avital, N., Shamay, M. & Kobiler, O. Abortive herpes simplex virus infection of nonneuronal cells results in quiescent viral genomes that can reactivate. Proc. Natl. Acad. Sci. 117, 635\u2013640 (2020).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"5188_CR41","first-page":"1","volume":"45","author":"K Dam","year":"2000","unstructured":"Dam, K. & Argu, W. Herpes simplex virus: the importance of asymptomatic shedding. J. Antimicrob. Chemother. 45, 1\u20138 (2000).","journal-title":"J. Antimicrob. Chemother."},{"key":"5188_CR42","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/molbev\/msy096","volume":"35","author":"S Kumar","year":"2018","unstructured":"Kumar, S., Stecher, G., Li, M., Knyaz, C. & Tamura, K. MEGA X: Molecular evolutionary genetics analysis across computing platforms. Mol. Biol. Evol. 35, 1547\u20131549 (2018).","journal-title":"Mol. Biol. Evol."},{"key":"5188_CR43","first-page":"95","volume":"41","author":"TA Hall","year":"1999","unstructured":"Hall, T. A. BIOEDIT: a user-friendly biological sequence alignment editor and analysis program for Windows 95\/98\/ NT. Nucleic Acids Symp. Ser. 41, 95\u201398 (1999).","journal-title":"Nucleic Acids Symp. Ser."},{"key":"5188_CR44","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/jac\/dkm182","volume":"60","author":"S Biswas","year":"2007","unstructured":"Biswas, S., Smith, C. & Field, H. J. Detection of HSV-1 variants highly resistant to the helicase\u2013primase inhibitor BAY 57\u20131293 at high frequency in 2 of 10 recent clinical isolates of HSV-1. J. Antimicrob. Chemother. 60, 274\u2013279 (2007).","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05188-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05188-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05188-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T21:41:19Z","timestamp":1669326079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05188-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["5188"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-05188-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]},"assertion":[{"value":"18 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1345"}}